Contrast Enhanced Ultrasound Market Rising With Growth In New Technology Trends Research By 2027

 

The global contrast enhanced ultrasound market size is estimated to reach USD 1.9 billion by 2027, expanding at a CAGR of 3.5%, according to a new report by Grand View Research, Inc. Introduction of affordable dyes, increasing sonography procedural volume, and contrast imaging modes becoming an integral feature of ultrasound systems are the prominent factors driving the market.

The increasing prevalence of cardiovascular diseases, liver lesions, renal lesions, gastrointestinal diseases, and vascular diseases globally is anticipated to boost the market growth, as these are major areas of clinical application of Contrast-enhanced Ultrasound (CEUS) systems.

The presence of several potential benefits in CEUS such as being completely radiation-free, quick, cost-efficient, and patient-friendly, in comparison to the contrast-enhanced CT/MRI, is expected to propel the growth of the market.

Increasing approvals of CEUS by regulatory bodies for new indications are expected to propel the growth of the market during the forecast period. For instance, the ultrasound dyes which were originally indicated for cardiac imaging have received an extension of indication for pediatric and liver imaging in several countries.

The usage of contrast agents with a standard ultrasound system enhances diagnostic efficiency, accuracy, and experience. Therefore, its growing utilization rate in ultrasonography specifically to examine complex structures of the cardiac, renal, liver, and vascular systems is driving the market. The introduction of affordable contrast agents, increasing ultrasound procedural volume, and contrast imaging modes becoming an integral feature of ultrasound systems are the prominent factors driving the market. For instance, in October 2020, Siemens Healthineers launched a state-of-the-art ultrasound technology called “Acuson Redwood” having in-built software systems to perform contrast-enhanced ultrasound procedures efficiently.

Have a Query? Ask Our Expert:

https://www.grandviewresearch.com/inquiry/450924/ibb

Contrast Enhanced Ultrasound Market Report Highlights

• Based on product, the equipment segment held the largest revenue share in 2020. This can be attributed to the largest installed base of sonography technology compatible with CEUS
• The contrast agents segment is expected to grow at the fastest rate of 4.0% during the forecast period owing to its approval of usage in the liver and pediatric imaging by the FDA
• Based on type, the non-targeted segment held the largest revenue share in 2020 as most of the commercially available dyes are non-targeted agents
• Numerous clinical trials conducted to determine the potential of diagnostic and therapeutic application of targeted imaging dyes in cancer care are expected to drive the segment during the forecast period
• The hospitals segment held the largest market share in 2020 owing to the increasing number of emergency visits with medical conditions such as abdominal pain, abdominal/thoracic trauma, and cardiac complications
• The clinics segment is anticipated to witness lucrative growth over the forecast period owing to the realization of economic and patient care benefits with the adoption of sonography devices in practice among physicians at primary and secondary care
• In Asia Pacific, the market is expected to grow at the fastest rate owing to the limited accessibility to advanced CT/MRI imaging modalities such as CT and MRI, and the growing burden of cardiovascular disorders in China and India.

A wide range of potential advantages of Contrast-enhanced Ultrasound (CEUS) such as being completely radiation-free, quick, cost-efficient, and patient-friendly in comparison to the contrast-enhanced CT and MRI is expected to propel market growth. For instance, an abdominal CEUS can eliminate the need for other tests such as CT or MRI, saving unnecessary cost and time. Additionally, contrast-enhanced ultrasound is specifically helpful in patients with renal insufficiency, claustrophobia or facing difficulties to lay still during contrast-enhanced CT or MRI scans

Key companies are observed to be making significant investments in research activities to generate clinical evidence to present their products as superior over available alternatives. For instance, in March 2020, Lantheus Medical Imaging, Inc. revealed disappointing results of one of its two clinical studies conducted to compare the reproducibility and accuracy of its ultrasound contrast agent with non-contrast MRI in the measurement of left ventricular injection fraction. The market players to strengthen their presence in the market are adopting various strategies such as mergers and acquisitions, product launch, entering joint ventures, and partnerships. For instance, in March 2020, GE healthcare entered into a partnership with Daiichi Sankyo to receive the market authorization rights of Japan of its ultrasound contrast agents - Sonazoid. Some of the prominent players in the contrast-enhanced ultrasound market include:

• Lantheus Medical Imaging, Inc.
• Bracco Diagnostic Inc.
• General Electric
• Siemens Healthcare GmbH
• nanoPET Pharma GmbH
• ESAOTE SpA
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

For More Information:www.grandviewresearch.com